EP Patent
EP4204011A4 — RADIOPHARMACEUTICAL PRODUCTS AND PROCESSES
Assigned to Centre for Probe Development and Commercialization · Expires 2025-06-18 · 1y expired
What this patent protects
Patent listed against lutetium-lu-177-dotatate.
Drugs covered by this patent
- lutetium-lu-177-dotatate (Lutetium Lu 177 Dotatate) · National Cancer Institute (NCI)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.